In this article, we will discuss Louis Navellier’s Top 10 Long-Term Stock Picks.
US stocks have advanced to record highs while shrugging off the lack of resolution in the US-Iran war and concerns over soaring inflation. The rally has come on the back of solid economic data, with investors absorbing robust earnings growth across most Wall Street counters. All the major US indexes have advanced to record highs, with the Nasdaq 100 leading the way with a 17% year-to-date gain.
“Everybody’s asking the same question: how much longer does this (rally) go on? There’s a lot of people that are loving this rally, but they’re also antsy at the same time,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “You have to be in it to win it, not just sitting on the sidelines watching the market go to all-time highs.”
While US markets are at an all-time high, the rally looks set to continue as valuations have fallen from peak levels. Whereas the S&P 500 traded at 23x forward earnings at the end of 2025, it is currently trading at about 22.5X, with the repricing more dramatic in the technology sector.
“It’s more than just the price recovery. Future earnings expectations have risen even faster, even as the conflict in Iran weighed on investors. But here’s the twist: the rebound was already underway before geopolitical clarity improved. That suggests this rally is being driven less by confidence around the war and more by faith in the fundamentals,” JPMorgan in a blog post.
Louis Navellier remains bullish about the overall stock market outlook, projecting the S&P 500 to rally by 20% in 2026. The increase will be driven by a 5% GDP growth rate and strong corporate earnings, according to the founder and Chief Investment Officer at Navellier & Associates.
Consequently, Navellier remains heavily invested in high-quality companies with an impressive track record in earnings growth. His investment portfolio is also well-positioned to benefit from the AI boom that is still underway. With that in mind, let’s take a look at some of Louis Navellier’s top long-term stock picks.
Louis Navellier of Navellier & Associates
Our Methodology
For this list, we picked stocks from Louis Navellier’s 13F portfolio as of the end of the first quarter of 2026. We settled on stocks that have been in Louis Navellier’s 13F portfolio consistently for the past five years. These stocks are also popular among other hedge funds in Q4 2025. Finally, the stocks are ranked in ascending order based on Navellier & Associates equity stakes in them.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Louis Navellier’s Top Long-Term Stock Picks
10. Chevron Corporation (NYSE:CVX)
Navellier & Associates Equity Stake: $2.52 Million
Navellier & Associates’ First Major Purchase: Q1 2019
Number of Hedge Fund Holders: 86
Chevron Corporation (NYSE:CVX) is one of Louis Navellier’s top long-term stock picks. On May 14, Chevron Corp (NYSE: CVX) reached an agreement to sell several Asia Pacific refining and retail assets to Japan’s Eneos. The company is poised to generate $2.17 billion from the divestment as it continues to streamline its international portfolio.
Some of the assets the company is offloading include downstream fuels and lubricants marketing businesses in Singapore, Malaysia, the Philippines, Australia, Vietnam, and Indonesia. The divestment is poised to close next year. Eneos is to acquire retail assets as it widens its operations overseas and strengthens its presence in Singapore, Asia’s oil trading and supply hub.
Chevron has been in the market to divest refining and storage assets to streamline its operations and reduce costs. Earlier in the year, the US energy giant had already sold its Hong Kong retail stations for $270 million.
Chevron Corporation (NYSE:CVX) is a leading global integrated energy company that explores for, produces, and transports crude oil and natural gas; refines, markets, and distributes transportation fuels and lubricants; and manufactures petrochemicals. They are focused on delivering traditional energy while investing in lower-carbon solutions.
9. KLA Corporation (NASDAQ:KLAC)
Navellier & Associates Equity Stake: $3.19 Million
Navellier & Associates’ First Major Purchase: Q1 2017
Number of Hedge Fund Holders: 67
KLA Corporation (NASDAQ:KLAC) is one of Louis Navellier’s top long-term stock picks. On May 1, analysts at Argus raised their price target for KLA Corporation (NASDAQ:KLAC) to $1950 from $1750 and reiterated a Buy rating on the stock.
The price target hike comes on the heels of KLA Corp delivering strong March-quarter results that exceeded the midpoint of its guidance ranges. Strong business momentum allowed the company to achieve revenue and earnings growth, setting the stage for an impressive year. Revenue in the quarter totaled $3.415 billion, above the midpoint guidance of $3.35 billion, as diluted earnings per share totaled $9.40, above the midpoint of the guidance.
The better-than-expected results came as KLA Corp continued to benefit from the global AI infrastructure build-out across all the major growth vectors of foundry/logic, memory, advanced packaging, and services. Similarly, analysts at Argus remain bullish on KLA Corp’s long-term outlook, owing to a demand build-up for process control and metrology solutions.
KLA Corporation (NASDAQ:KLAC) is a leading global supplier of process control and yield management solutions for the semiconductor and electronics industries. They develop inspection, metrology, and data analytics tools—often powered by AI—that allow chipmakers to identify defects and measure performance on wafers and reticles during manufacturing.
8. Johnson & Johnson (NYSE:JNJ)
Navellier & Associates Equity Stake: $3.44 Million
Navellier & Associates’ First Major Purchase: Q2 2016
Number of Hedge Fund Holders: 104
Johnson & Johnson (NYSE:JNJ) is one of Navellier’s top long-term stock picks. On May 12, Johnson & Johnson (NYSE:JNJ) reaffirmed its push for opportunities in the treatment of calcified coronary artery disease, which affects about 315 million people worldwide. The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation intravascular lithotripsy catheter.
An upgrade to the Shockwave C2+, the lithotripsy catheter features improved deliverability, enhanced lesion-crossing capabilities, and new repositioning functions. It also leverages ultrasonic acoustic pressure to disrupt plaque in coronary arteries. The catheter also comes with a more flexible shaft, a balloon, and marker bands to navigate tortuous arteries with ease.
With a working length of 138 centimeters and two emitters integrated into a balloon, the catheter can deliver up to 120 pulses and 240 shockwaves. While the device is currently available only in the US and Japan, Johnson & Johnson is working on making it available in Canada and Europe.
Johnson & Johnson (NYSE:JNJ) is a global healthcare company that researches, develops, and manufactures innovative medicines (pharmaceuticals) and medical technology (MedTech) products. It focuses on treating complex diseases, advancing surgical care, and improving patient outcomes in areas such as cancer, immunology, and orthopedics.
7. Amgen Inc. (NASDAQ:AMGN)
Navellier & Associates Equity Stake: $4.21 Million
Navellier & Associates’ First Major Purchase: Q2 2015
Number of Hedge Fund Holders: 70
Amgen Inc. (NASDAQ:AMGN) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on Amgen Inc. (NASDAQ:AMGN) but lowered the price target to $427 from $432.
The new price target still represents significant upside potential as the research firm expects the company to deliver top-line revenue growth for both 2026 and 2027. The new price target is also less dependent on key commercial products, including Repatha, Tezspire, and Evenity.
The research firm expects continued strength in the rare disease segment, especially Uplizna, to accelerate underlying growth. Uplizna sales were up 188% year over year to $262 million in the first quarter, driven by volume growth.
Tepezza, an FDA-approved prescription medication for treating Thyroid Eye Disease (TED) in adults, is also expected to drive the growth following strong Phase III data. In the first quarter, Tepezza sales increased 29% year over year to $490 million, driven by higher inventory levels.
Amgen Inc. (NASDAQ:AMGN) is a leading global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics, focusing on treating serious illnesses in oncology, cardiology, bone health, inflammation, and rare diseases. As a pioneer in using living cells to create biologic medicines, Amgen serves millions of patients worldwide.
6. AbbVie Inc. (NYSE:ABBV)
Navellier & Associates Equity Stake: $6.16 Million
Navellier & Associates’ First Major Purchase: Q1 2016
Number of Hedge Fund Holders: 84
AbbVie Inc. (NYSE:ABBV) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on AbbVie (NYSE: ABBV), buoyed by the company’s inflammatory bowel disease (IBD) pipeline.
The research firm also raised its price target to $298 from $294, as management moves forward with Skyrizi in combination with its novel α4β7-directed antibody, ABBV-382. According to Piper Sandler, the advancement of novel combination approaches in IBD is a welcome development that strengthens AbbVie’s edge, given the competitive nature of the IBD drug development landscape.
Abbvie has already delivered and presented top-line findings affirming SKYRIZ as a potential treatment in Crohn’s disease and ulcerative colitis. It has also reiterated its focus on advancing the understanding of IBD to raise the standard of care through scientific innovation and a broad portfolio.
AbbVie has also made an application to the U.S. Food and Drug Administration (FDA) seeking approval for Skyrizi for subcutaneous (SC) induction in the treatment of adult patients with Crohn’s disease (CD).
AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that discovers, develops, and markets advanced therapies to treat complex, severe health conditions. The company focuses on specialized areas, including immunology, oncology, neuroscience, eye care, and aesthetics, aiming to improve patient health outcomes worldwide.
While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the Louis Navellier’s Top 5 Long-Term Stock Picks.
Disclosure: None. Follow Insider Monkey on Google News.
